BIOTECHNOLOGY

SARS-Hunter gives the possibility to hospitals to isolate the antibodies from plasma to be given as therapy and increases the chances of success of treatment, while reducing the side effects of plasma therapy given today.

The paper, entitled “Late pregnancy screening for preeclampsia with a urinary point-of-care test for misfolded proteins”, was written by collaborators from China Medical University's Shengjing Hospital and Columbia University Medical Center in New York and demonstrates the ability of the test to detect preeclampsia at a high level of accuracy in women admitted to the hospital for any reason. The findings included over 1,500 women and were published in the peer-reviewed journal PLOS One.

The SOLIUS technology stimulates the production of vitamin D in the skin using a narrow spectrum of ultraviolet B (UVB) light.

Intended to be used on HIV-1 Group M viruses from patients diagnosed with HIV infection, the assays deliver standardized, open and flexible solution suited to clinical settings performing sequencing through Capillary Electrophoresis and Next Generation Sequencing (NGS) systems.

Everlywell's EUA is the first to be issued to a digital health company such as Everlywell, which connects people and organizations with laboratory testing and is not a laboratory or diagnostics manufacturer.

The research team has just secured a grant of eight million Euros from the European & Developing Countries Clinical Trials Partnership a program supported by the European Union*. Part of this will be used to evaluate the immune status of people suffering from a disfiguring type of leishmaniasis, caused by a tiny single-celled parasite. Leishmaniasis primarily affects people in South America, East Africa and Asia, especially those weakened by malnutrition and poverty.

By combining Mologic’s independently verified COVID-19 lateral flow test with BioSure’s market-leading design, the companies have created a self-test for COVID-19 that can be used without any training being required.

Particularly in the early phase of COVID-19 infection, the direct and precise diagnostic of the pathogen is key. PCR is the method of choice to detect acute coronavirus infections.

Debiotech will be collaborating with vaccine companies, foundations and public organizations, using its unique DebioJect™ COVID-19 Microneedle, to improve the effectiveness of COVID-19 vaccines by reducing the necessary dose to achieve a sufficient immune response.